Immunomodulation of NK, NKT and B/T cell subtypes in relapsed/refractory multiple myeloma patients treated with pomalidomide along with velcade and dexamethasone and its association with improved progression-free survival

Immunomodulation of NK, NKT and B/T cell subtypes in relapsed/refractory multiple myeloma patients treated with pomalidomide along with velcade and dexamethasone and its association with improved progression-free survival

BackgroundMultiple Myeloma (MM) patients exhibit dysregulated immune system, which is further weakened by chemotherapeutic agents. While cereblon-modulating agents, such as pomalidomide and lenalidomide, have been found to improve the immune profile, the efficacy of their impact in combination with...

Full description

Bibliographic Details
Main Authors: Rao Prabhala, William E. Pierceall, Mehmet Samur, Lakshmi B. Potluri, Kevin Hong, Teresa Peluso, Srikanth Talluri, Angela Wang, Aishwarya Katiki, Sahan D. Vangala, Michael Buonopane, Vaishnavi Bade, Hannah Seah, Arthur Krogman, Sanika Derebail, Mariateresa Fulciniti, Suzan B. Lazo, Paul Richardson, Kenneth Anderson, Jill Corre, Herve Avet-Loiseau, Anjan Thakurta, Nikhil Munshi
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-12-01
Series:Frontiers in Oncology
Subjects:
myeloma
pomalidomide
NK cells
B cells
and T cells
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1271807/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1271807/full

Similar Items